Quantitative MRI and 1H-MRS in Traumatic Brain Injury

定量 MRI 和 1H-MRS 在创伤性脑损伤中的应用

基本信息

  • 批准号:
    7990385
  • 负责人:
  • 金额:
    $ 55.9万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2000
  • 资助国家:
    美国
  • 起止时间:
    2000-09-15 至 2012-11-30
  • 项目状态:
    已结题

项目摘要

Mild traumatic brain injury (MTBI) and post concussion syndrome (PCS) are acknowledged as highly significant public health problems affecting over 1.2 million Americans in both civilian and combat military sectors at a cost exceeding $17 billion annually. Troubling, therefore, is the fact that conventional clinical radiological tools such as computed tomography (CT) and magnetic resonance (MR) imaging (MRI) often fail, to detect brain abnormalities ensuing from MTBI that can account for the array of physical, cognitive and emotional/behavioral symptoms defining PCS. Since there are no good animal models for MTBI, the current teaching is that in humans, PCS pathology is the result of diffuse axonal injury (DAI) occurring predominantly in stereotypical locations including the gray-white junction, corpus callosum, and midbrain. Contrary to this commonly accepted principle, we hypothesize (Central Hypothesis) that the primary site of injury in MTBI is the thalamus. This hypothesis is based upon the preliminary results we have gathered. This data is supported by: (1) literature demonstrating neuropathological injury to this structure; and (2) the ability to ascribe a multitude of post concussive symptoms to one site. Thalamic damage results in structural and metabolic abnormalities that can be quantified by MR (diffusion kurtosis, magnetic field correlation, blood perfusion, and volumetric measures) and MR spectroscopy (MRS) and is responsible for PCS. To test this hypothesis we propose three Specific Aims: Specific Aim 1: to establish, within the first month after MTBI, with quantitative MR at high-field (3T), evidence of microstructural, perfusional, and biochemical thalamic abnormalities, in 20 new patients accrued annually, compared with age/sex matched controls. Specific Aim 2: to associate post concussive symptoms and a battery of neuropsychological tests with structural and biochemical metrics. Specific Aim 3: to serially follow up each patient annually to enable identification and validation of quantitative predictive metrics of clinical outcome in MTBI. Health Relevance: This research is designed to: (1) improve our diagnostic acumen and understanding of the MTBI "epidemic"; (2) provide objective metrics to detect and quantify MTBI; (3) enable the prediction of outcome; and (4) contribute new insights into the pathophysiology of MTBI that will potentially result in better treatment for these patients.
轻度创伤性脑损伤(MTBI)和脑震荡后综合征(PCS)被认为是高度 影响120多万美国平民和战斗军人的重大公共卫生问题 每年花费超过170亿美元。因此,令人不安的是,传统的临床 诸如计算机断层摄影(CT)和磁共振(MR)成像(MRI)的放射学工具通常 未能检测到MTBI引起的大脑异常,这些异常可以解释身体,认知和 定义PCS的情绪/行为症状。由于没有良好的MTBI动物模型, 在人类中,PCS病理学是弥漫性轴索损伤(DAI)的结果, 在包括灰白交界处、胼胝体和中脑在内的常规位置。与此相反 根据公认的原则,我们假设(中心假设), MTBI是丘脑。这个假设是基于我们收集的初步结果。该数据 支持:(1)证明该结构神经病理损伤的文献;和(2) 将多种脑震荡后症状归咎于一个部位丘脑损伤导致结构和 可以通过MR量化的代谢异常(扩散峰度、磁场相关性、血液动力学、血液动力学), 灌注和体积测量)和MR波谱(MRS),并负责PCS。 为了验证这一假设,我们提出了三个具体目标:具体目标1:在第一个月内建立 MTBI后,高场(3 T)定量MR,显微结构、灌注和生物化学证据 与年龄/性别匹配的对照组相比,20例新患者的丘脑异常每年增加。 具体目标2:将脑震荡后症状和一系列神经心理学测试与 结构和生化指标。具体目标3:每年对每位患者进行连续随访, MTBI中临床结果定量预测指标的识别和验证。 健康相关性:这项研究旨在:(1)提高我们的诊断敏锐度, 对MTBI“流行病”的理解;(2)提供检测和量化MTBI的客观指标;(3) 能够预测结果;(4)对MTBI的病理生理学提供新的见解 这可能会为这些患者带来更好的治疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Yvonne W Lui其他文献

Yvonne W Lui的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Yvonne W Lui', 18)}}的其他基金

Optimized Sodium MR Imaging at Clinical Field Strength to Study in vivo Sodium Signal in Mild Traumatic Brain Injury
在临床场强下优化钠 MR 成像,研究轻度创伤性脑损伤中的体内钠信号
  • 批准号:
    10638948
  • 财政年份:
    2023
  • 资助金额:
    $ 55.9万
  • 项目类别:
Pattern Classification Using Magnetic Resonance Imaging in Traumatic Brain Injury
使用磁共振成像对创伤性脑损伤进行模式分类
  • 批准号:
    9295067
  • 财政年份:
    2016
  • 资助金额:
    $ 55.9万
  • 项目类别:
Quantitative MRI and 1H-MRS in Traumatic Brain Injury
定量 MRI 和 1H-MRS 在创伤性脑损伤中的应用
  • 批准号:
    9193482
  • 财政年份:
    2016
  • 资助金额:
    $ 55.9万
  • 项目类别:
Quantitative MRI and 1H-MRS in Traumatic Brain Injury
定量 MRI 和 1H-MRS 在创伤性脑损伤中的应用
  • 批准号:
    8843551
  • 财政年份:
    2000
  • 资助金额:
    $ 55.9万
  • 项目类别:
Quantitative MRI and 1H-MRS in Traumatic Brain Injury
定量 MRI 和 1H-MRS 在创伤性脑损伤中的应用
  • 批准号:
    8629066
  • 财政年份:
    2000
  • 资助金额:
    $ 55.9万
  • 项目类别:
Quantitative MRI and 1H-MRS in Traumatic Brain Injury
定量 MRI 和 1H-MRS 在创伤性脑损伤中的应用
  • 批准号:
    9277596
  • 财政年份:
    2000
  • 资助金额:
    $ 55.9万
  • 项目类别:
Quantitative MRI and 1H-MRS in Traumatic Brain Injury
定量 MRI 和 1H-MRS 在创伤性脑损伤中的应用
  • 批准号:
    8727675
  • 财政年份:
    2000
  • 资助金额:
    $ 55.9万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 55.9万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 55.9万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 55.9万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 55.9万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 55.9万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 55.9万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 55.9万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 55.9万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 55.9万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 55.9万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了